A somatostatin analogue, anti-hormone drug that is indicated for treatment in patients with metastatic carcinoid tumors, carcinoid syndrome and related NETs. It is given by sub cutaneously injection 2-4 times per day, and then the injection may be changed to once every 3-4 weeks using a long acting release (LAR) dosage. Continous infusion via (insulin) pump has been rarely used by some physicians for patients requiring very large dosage.. Octreotide (Sandostatin®) often improves symptoms of the carcinoid syndrome (severe diarrhea and flushing). In some cases, this anti-hormone drug inhibits and sometimes reverses the growth of the tumors. Manufactured by Novartis.